Moreover, exposure by itself does not necessarily result in disease. "We have to recognize that things are not driven by just exposure alone in terms of some of these very long-term outcomes," Groopman says. "There is certainly an interaction with respect to the host's genetic susceptibility that is playing an important role."
The fact that gene-environment interactions profoundly affect whether an environmental exposure may lead to disease is a relatively new factor in the equation. Says Groopman, "We're entering a completely new world now, a world where our genetic understanding is leading to the development of an incredible panoply of early detection disease biomarkers. What's being developed now as a result of the genetic revolution, the Human Genome Project, and . . . the Environmental Genome Project is the fact -Lynn Goldman that we are beginning to identify individuals at subclinical disease state [before a disease is manifested], and we need to now integrate into our paradigm what role exposure will play in either exacerbating or blunting the blossoming of that disease state when it becomes a clinically defined identity." The Environmental Genome Project is a multiagency effort to systematically identify the alleles of some 200 environmental susceptibility genes in the U.S. population. Risk Assessment and Policy "Our ability to make these measurements, do these analyses, understand the meaning of these biomarkers really only has importance if we can utilize these data in a public health setting in order to reduce morbidity and mortality of disease in individuals," says Groopman.
Lioy agrees: "We need to know whether body burdens of lead, polychlorinated biphenyls, dioxins, volatile organics, and other air and water pollutants are increasing, remaining at the same levels, or decreasing as regulations meant to decrease the levels of these chemicals in the environment are designed and implemented." In general, the community needs to do a better job of determining what works in reducing human exposure. Lucier says, "If it doesn't result in a reduction in disease then it hasn't been successful."
Policy makers are confident more answers will be coming in the next decade. "The field of exposure assessment can address many of our most visible health concerns," Lucier says. "What's kept it from succeeding in the past has largely been people's inability to work together effectively."
The To make it happen, more researchers and new methods and tools are needed to stimulate the field. Without effective use of experimental data, the decisions that can be made about chemical exposures are limited. "There is a frustration in the whole regulatory arena that many epidemiological studies for exposure assessment don't easily lend themselves to the risk assessment mantra," says Goldman, "and the exposure assessment information doesn't readily lend itself to outcomes research." Advances, especially in analytical technology and molecular biology, may change that. And, says Lucier, "We need cross-training so our researchers will think like a toxicologist and an epidemiologist at the same time. We don't have those kind of people trained today."
Experts predict that in the future improved exposure assessment will play a leading role in the prevention of environmental disease. Says Jackson, "Ten years from now in the field of environmental health, it will seem strange to talk about exposure without looking at the actual human dose."
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